UniSuper Management Pty Ltd Makes New $913,000 Investment in Glaukos Co. (NYSE:GKOS)

UniSuper Management Pty Ltd purchased a new position in shares of Glaukos Co. (NYSE:GKOS) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 9,684 shares of the medical instruments supplier’s stock, valued at approximately $913,000.

Other large investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its holdings in shares of Glaukos by 3.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 923,526 shares of the medical instruments supplier’s stock valued at $73,412,000 after buying an additional 31,213 shares during the last quarter. Jump Financial LLC boosted its holdings in shares of Glaukos by 513.3% in the 4th quarter. Jump Financial LLC now owns 47,589 shares of the medical instruments supplier’s stock valued at $3,783,000 after buying an additional 39,829 shares during the last quarter. Norges Bank acquired a new stake in shares of Glaukos in the 4th quarter valued at approximately $28,807,000. Nomura Holdings Inc. boosted its holdings in shares of Glaukos by 3.2% in the 4th quarter. Nomura Holdings Inc. now owns 232,034 shares of the medical instruments supplier’s stock valued at $18,444,000 after buying an additional 7,146 shares during the last quarter. Finally, Jennison Associates LLC bought a new stake in Glaukos in the 4th quarter valued at $608,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Analyst Ratings Changes

GKOS has been the topic of several recent research reports. Wells Fargo & Company increased their price objective on Glaukos from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday, June 3rd. JPMorgan Chase & Co. raised their price objective on Glaukos from $108.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, May 2nd. StockNews.com lowered Glaukos from a “hold” rating to a “sell” rating in a research note on Saturday, July 13th. Jefferies Financial Group raised Glaukos from a “hold” rating to a “buy” rating and lifted their price target for the company from $84.00 to $125.00 in a research note on Monday, May 6th. Finally, Stifel Nicolaus lifted their price target on Glaukos from $110.00 to $130.00 and gave the company a “buy” rating in a research note on Wednesday, June 5th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $120.64.

Glaukos Price Performance

Shares of NYSE:GKOS traded down $0.97 during mid-day trading on Thursday, hitting $121.63. 29,419 shares of the company traded hands, compared to its average volume of 589,724. The company has a quick ratio of 4.68, a current ratio of 5.38 and a debt-to-equity ratio of 0.78. Glaukos Co. has a 12-month low of $59.22 and a 12-month high of $126.96. The stock has a 50-day moving average price of $115.30 and a two-hundred day moving average price of $101.35.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.12). The company had revenue of $85.60 million for the quarter, compared to analysts’ expectations of $79.60 million. Glaukos had a negative net margin of 43.15% and a negative return on equity of 24.69%. The firm’s quarterly revenue was up 15.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.59) EPS. On average, equities research analysts expect that Glaukos Co. will post -2.25 EPS for the current year.

Insider Activity at Glaukos

In other Glaukos news, COO Joseph E. Gilliam sold 2,059 shares of the business’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $105.52, for a total value of $217,265.68. Following the transaction, the chief operating officer now owns 101,845 shares of the company’s stock, valued at $10,746,684.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Glaukos news, COO Joseph E. Gilliam sold 2,059 shares of the business’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $105.52, for a total value of $217,265.68. Following the transaction, the chief operating officer now owns 101,845 shares of the company’s stock, valued at $10,746,684.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Alex R. Thurman sold 442 shares of the business’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $105.69, for a total value of $46,714.98. Following the completion of the transaction, the chief financial officer now directly owns 52,090 shares in the company, valued at approximately $5,505,392.10. The disclosure for this sale can be found here. Insiders have sold a total of 21,444 shares of company stock valued at $2,411,171 over the last 90 days. Insiders own 6.40% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.